-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The concept of innovative drugs is proposed in comparison with generic drugs
.
According to the industry, compared with generic drugs, innovative drugs have more profit margins, and the policies and funds faced in recent years have also been greatly improved.
At the same time, the current domestic sales of innovative drugs only account for 5%, and there is considerable room for growth
.
Against a series of favorable backgrounds, many domestic pharmaceutical companies continue to increase their efforts in the construction of innovative drugs
.
For example, Zhongguancun Pharmaceutical will complete the refocusing of its development strategy in 2021 and actively build an innovative pharmaceutical industry group
.
In 2021, the company's R&D expenses will increase by 100.
38% year-on-year to 119 million yuan, and the number of R&D personnel will also increase from 230 in the same period of the previous year to 255
.
In the first quarter of 2022, the company's R&D expenses increased by 212.
94% year-on-year to 27.
0915 million yuan
.
The company stated that the substantial increase in research and development expenses was mainly due to the increased investment in the research and development of biological drugs by its subsidiary, Huasu Biotechnology (Beijing) Co.
,
Ltd.
It is reported that the company will start to set foot in biomedicine in 2021.
Through cooperation with scientific research institutions, all work such as project establishment, sequence construction, transfection, and cell line screening has been completed
.
Hengrui Medicine said that in 2021, the company's R&D investment will increase by 24.
34% year-on-year, reaching 6.
203 billion yuan, and the proportion of R&D investment in sales revenue will reach 23.
95%, a record high in the company's history
.
Under the background of high R&D investment, Hengrui Medicine's innovative drugs are also entering the harvest period
.
The data shows that by the end of 2021, the number of innovative drugs on the market has increased to 10, and 4 new indications of camrelizumab for injection have been approved one after another, and the total number of approved indications has reached 8, which is currently the most approved indications.
Domestic PD-1; Fluzoparib Capsules were approved for marketing for the second indication; Remazolam tosylate for injection was approved for marketing for the third indication
.
In 2021, 108 clinical approvals were obtained, 65 innovative drugs in clinical development stage (15 in phase 3 clinical stage, 4 in NDA stage), more than 250 domestic and foreign clinical projects, and 3 clinical trials were included in the breakthrough Sex therapy list, 7 international multi-center projects have entered the registration phase III clinical
.
As a pharmaceutical company driven by innovation and R&D, Simcere Pharma stated in its 2021 financial report that Simcere China has listed 5 innovative drugs with differentiated value, and the sales revenue of innovative drugs in 2021 will account for 62.
4% of the total revenue of the group.
%
.
In terms of R&D investment, it will reach 1.
417 billion yuan in 2021, accounting for 28.
3% of the total revenue, and create nearly 60 innovative R&D pipelines
.
It is reported that Simcere's own R&D technology platform has deployed multiple varieties in cutting-edge technology fields such as tumor immune double antibodies, multispecific antibodies, synthetic lethal, AI drugs, Treg fusion proteins, and autoimmune antibody-drug conjugates (ADCs).
It is expected to bring innovations with more clinical value
.
In 2022, the company is expected to add nearly 10 INDs with Sino-US dual reporting, more than half of which are self-developed
.
In recent years, under the influence of multiple factors such as policies, capital, and talents, the number of innovative drugs in China has grown exponentially
.
Some analysts said that before 2018, innovative drug companies had been facing a common pain point: financing difficulties
.
2018 was a watershed year.
In April 2018, the Hong Kong Stock Exchange launched a major listing reform in the past 25 years.
The door to public financing was opened to unprofitable biopharmaceutical companies, setting off a trend of IPO listings for pharmaceuticals and biotechnology.
Promote the international development of core products of innovative drug companies and the advancement of clinical trials of other products in the pipeline
.
Analysts said that China's local innovation has gone through the initial stage of "savage growth", and is now ushering in the development stage of "big waves".
What is worth looking forward to is that after the "break", the real innovative drugs will definitely be left behind
.
But at the same time, how to break through the bottleneck of innovation quality and meet the truly unmet needs of patients also puts forward higher requirements for pharmaceutical companies and the industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to the industry, compared with generic drugs, innovative drugs have more profit margins, and the policies and funds faced in recent years have also been greatly improved.
At the same time, the current domestic sales of innovative drugs only account for 5%, and there is considerable room for growth
.
Against a series of favorable backgrounds, many domestic pharmaceutical companies continue to increase their efforts in the construction of innovative drugs
.
For example, Zhongguancun Pharmaceutical will complete the refocusing of its development strategy in 2021 and actively build an innovative pharmaceutical industry group
.
In 2021, the company's R&D expenses will increase by 100.
38% year-on-year to 119 million yuan, and the number of R&D personnel will also increase from 230 in the same period of the previous year to 255
.
In the first quarter of 2022, the company's R&D expenses increased by 212.
94% year-on-year to 27.
0915 million yuan
.
The company stated that the substantial increase in research and development expenses was mainly due to the increased investment in the research and development of biological drugs by its subsidiary, Huasu Biotechnology (Beijing) Co.
,
Ltd.
It is reported that the company will start to set foot in biomedicine in 2021.
Through cooperation with scientific research institutions, all work such as project establishment, sequence construction, transfection, and cell line screening has been completed
.
Hengrui Medicine said that in 2021, the company's R&D investment will increase by 24.
34% year-on-year, reaching 6.
203 billion yuan, and the proportion of R&D investment in sales revenue will reach 23.
95%, a record high in the company's history
.
Under the background of high R&D investment, Hengrui Medicine's innovative drugs are also entering the harvest period
.
The data shows that by the end of 2021, the number of innovative drugs on the market has increased to 10, and 4 new indications of camrelizumab for injection have been approved one after another, and the total number of approved indications has reached 8, which is currently the most approved indications.
Domestic PD-1; Fluzoparib Capsules were approved for marketing for the second indication; Remazolam tosylate for injection was approved for marketing for the third indication
.
In 2021, 108 clinical approvals were obtained, 65 innovative drugs in clinical development stage (15 in phase 3 clinical stage, 4 in NDA stage), more than 250 domestic and foreign clinical projects, and 3 clinical trials were included in the breakthrough Sex therapy list, 7 international multi-center projects have entered the registration phase III clinical
.
As a pharmaceutical company driven by innovation and R&D, Simcere Pharma stated in its 2021 financial report that Simcere China has listed 5 innovative drugs with differentiated value, and the sales revenue of innovative drugs in 2021 will account for 62.
4% of the total revenue of the group.
%
.
In terms of R&D investment, it will reach 1.
417 billion yuan in 2021, accounting for 28.
3% of the total revenue, and create nearly 60 innovative R&D pipelines
.
It is reported that Simcere's own R&D technology platform has deployed multiple varieties in cutting-edge technology fields such as tumor immune double antibodies, multispecific antibodies, synthetic lethal, AI drugs, Treg fusion proteins, and autoimmune antibody-drug conjugates (ADCs).
It is expected to bring innovations with more clinical value
.
In 2022, the company is expected to add nearly 10 INDs with Sino-US dual reporting, more than half of which are self-developed
.
In recent years, under the influence of multiple factors such as policies, capital, and talents, the number of innovative drugs in China has grown exponentially
.
Some analysts said that before 2018, innovative drug companies had been facing a common pain point: financing difficulties
.
2018 was a watershed year.
In April 2018, the Hong Kong Stock Exchange launched a major listing reform in the past 25 years.
The door to public financing was opened to unprofitable biopharmaceutical companies, setting off a trend of IPO listings for pharmaceuticals and biotechnology.
Promote the international development of core products of innovative drug companies and the advancement of clinical trials of other products in the pipeline
.
Analysts said that China's local innovation has gone through the initial stage of "savage growth", and is now ushering in the development stage of "big waves".
What is worth looking forward to is that after the "break", the real innovative drugs will definitely be left behind
.
But at the same time, how to break through the bottleneck of innovation quality and meet the truly unmet needs of patients also puts forward higher requirements for pharmaceutical companies and the industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
